Amedisys (NASDAQ:AMED) Sets New 52-Week High at $97.66

Amedisys, Inc. (NASDAQ:AMED)’s stock price hit a new 52-week high on Tuesday . The stock traded as high as $97.66 and last traded at $97.34, with a volume of 265651 shares trading hands. The stock had previously closed at $97.21.

Analyst Upgrades and Downgrades

AMED has been the subject of several recent analyst reports. William Blair lowered shares of Amedisys from an “outperform” rating to a “market perform” rating in a research note on Monday, July 1st. Royal Bank of Canada increased their price objective on shares of Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 25th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $101.00 target price on shares of Amedisys in a report on Thursday, April 25th. StockNews.com upgraded Amedisys from a “hold” rating to a “buy” rating in a report on Saturday, May 4th. Finally, Raymond James reissued a “market perform” rating on shares of Amedisys in a research report on Tuesday, March 26th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $100.67.

Amedisys Price Performance

The business’s 50-day moving average price is $94.11 and its 200 day moving average price is $93.59. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.09. The stock has a market capitalization of $3.21 billion, a PE ratio of -153.62, a price-to-earnings-growth ratio of 2.38 and a beta of 0.79.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. The firm had revenue of $571.41 million during the quarter, compared to the consensus estimate of $565.38 million. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter last year, the company posted $1.00 EPS. Research analysts forecast that Amedisys, Inc. will post 4.57 earnings per share for the current year.

Institutional Trading of Amedisys

A number of hedge funds have recently made changes to their positions in the stock. Banque Cantonale Vaudoise bought a new position in Amedisys during the first quarter valued at approximately $60,000. Covestor Ltd raised its position in Amedisys by 134.2% in the 1st quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock worth $72,000 after purchasing an additional 447 shares during the period. Cetera Trust Company N.A bought a new stake in Amedisys in the fourth quarter worth $215,000. CWM LLC boosted its position in Amedisys by 40.4% during the fourth quarter. CWM LLC now owns 2,629 shares of the health services provider’s stock valued at $250,000 after buying an additional 757 shares during the period. Finally, Contravisory Investment Management Inc. bought a new position in shares of Amedisys during the fourth quarter valued at about $258,000. 94.36% of the stock is owned by institutional investors.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.